TISIDB

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space, extracellular matrix, basement membrane. Note=Major component.
Domain	PF00052 Laminin B (Domain IV) PF00053 Laminin EGF domain PF00054 Laminin G domain PF02210 Laminin G domain PF06008 Laminin Domain I PF06009 Laminin Domain II PF00055 Laminin N-terminal (Domain VI)
Function	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.

> Gene Ontology [ TOP ]
Biological Process	GO:0007271 synaptic transmission, cholinergic GO:0007272 ensheathment of neurons GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007422 peripheral nervous system development GO:0007517 muscle organ development GO:0008366 axon ensheathment GO:0010001 glial cell differentiation GO:0014037 Schwann cell differentiation GO:0014044 Schwann cell development GO:0021782 glial cell development GO:0022011 myelination in peripheral nervous system GO:0030198 extracellular matrix organization GO:0032222 regulation of synaptic transmission, cholinergic GO:0032224 positive regulation of synaptic transmission, cholinergic GO:0032292 peripheral nervous system axon ensheathment GO:0042063 gliogenesis GO:0042552 myelination GO:0043062 extracellular structure organization GO:0045995 regulation of embryonic development GO:0048667 cell morphogenesis involved in neuron differentiation GO:0050804 modulation of synaptic transmission GO:0050806 positive regulation of synaptic transmission GO:0061564 axon development GO:0097485 neuron projection guidance
Molecular Function	-
Cellular Component	GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0005605 basal lamina GO:0030425 dendrite GO:0042383 sarcolemma GO:0043197 dendritic spine GO:0044309 neuron spine GO:0044420 extracellular matrix component GO:0098794 postsynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04151 PI3K-Akt signaling pathway hsa04510 Focal adhesion hsa04512 ECM-receptor interaction
Reactome	R-HSA-3000178: ECM proteoglycans R-HSA-1474244: Extracellular matrix organization R-HSA-3000157: Laminin interactions R-HSA-8874081: MET activates PTK2 signaling R-HSA-8875878: MET promotes cell motility R-HSA-3000171: Non-integrin membrane-ECM interactions R-HSA-162582: Signal Transduction R-HSA-6806834: Signaling by MET

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between LAMA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of LAMA2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of LAMA2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.177	0.00799
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-2.248	0.00303
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.399	0.573
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.118	0.804
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.494	0.843
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.356	0.91
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.533	0.385
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.46	0.701
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.464	0.751
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.87	0.368
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.066	0.0876
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.413	0.0153

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of LAMA2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	33.3	-23.3	0.423
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	9.6	5.2	0.482
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	11.9	2.9	0.735
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	33.3	29.4	3.9	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	37.5	16.7	20.8	0.58
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	36.4	-5.6	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	44.4	0	44.4	0.00996
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	75	0	75	0.0242
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	3.7	6.8	0.393
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	0	13.6	0.279
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	0	20	0.294

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LAMA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LAMA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LAMA2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LAMA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of LAMA2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between LAMA2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	LAMA2
Name	laminin, alpha 2
Aliases	merosin; congenital muscular dystrophy; LAMM; laminin M chain; laminin-12 subunit alpha; laminin-2 subunit a ......
Chromosomal Location	6q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting LAMA2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse LAMA2